Abstract
Dr Reddy's Laboratories will release its quarterly results on October 23, 2026 after market close, with investors watching revenue, margins, and EPS amid a pullback in forecasts and a sharp quarter-on-quarter rebound last quarter in net profit.
Market Forecast
Based on the company’s forecast set, revenue for the current quarter is estimated at 84.66 billion in the reporting currency, implying a year-over-year decline of 3.46% and a modest sequential improvement versus the prior quarter’s 80.998 billion actual. The implied EBIT estimate is 7.20 billion with a year-over-year decline of 58.80%, and forecast EPS is 8.64, down 48.11% year over year; gross profit margin and net profit margin guidance were not explicitly provided in the forecast set, but last quarter’s gross profit margin stood at 46.52% and net profit margin at 5.50%. The main business remains anchored by global generics, while the most promising contribution is expected from the broader generics and API portfolio rationalization and launches; within this mix, global generics delivered 65.80 billion last quarter with other businesses and internal offsets netting to smaller contributions.
Last Quarter Review
Dr Reddy's Laboratories reported last quarter revenue of 80.998 billion in the reporting currency, a gross profit margin of 46.52%, net profit attributable to the parent company of 4.435 billion, a net profit margin of 5.50%, and adjusted EPS of 5.33 with a year-over-year decline of 68.68%. Net profit rebounded strongly on a quarter-on-quarter basis with a growth rate of 101.50%, supported by improved cost control and mix. Main business highlights: the global generics segment recorded 65.80 billion, while the pharmaceutical services and active ingredients business contributed 11.08 billion, with internal offsets and other items reducing the consolidated total; the reported revenue declined 5.51% year over year.
Current Quarter Outlook
Main business: Global generics
Global generics remains the primary revenue driver, contributing 65.80 billion last quarter. The current quarter estimate of 84.66 billion in consolidated revenue suggests a moderation in year-over-year growth at the group level, but sequentially, it points to a recovery path following last quarter’s decline of 5.51% year over year. The segment’s earnings trajectory will hinge on price dynamics in key markets, the cadence of new product launches, and channel restocking patterns. Management’s forecast implies EPS of 8.64 and EBIT of 7.20 billion, which, combined with last quarter’s 46.52% gross margin baseline, indicates a focus on maintaining operating leverage even as headline revenue trends soften year over year. Investors will monitor the spread between gross margin and net margin, given the prior quarter’s 5.50% net margin, to gauge how mix, input costs, and operating expenses evolve during the transition.
Most promising business: Portfolio launches and API/services
While the consolidated forecast points to a 3.46% year-over-year decline, the most promising areas near term lie in targeted launch pipelines across generics and steady contributions from pharmaceutical services and active ingredients. The latter delivered 11.08 billion last quarter and typically provides margin support through contract manufacturing and specialty APIs. Execution on launches—particularly in North America and Europe—could provide upside to the revenue and EPS estimates if volume gains offset price erosion. The quarter’s EBIT estimate decline of 58.80% year over year sets a conservative profit bar; if services mix improves and cost absorption normalizes, EBIT could outperform this baseline.
Key stock drivers this quarter
The most important swing factors are pricing in generics, the pace of new approvals and launches, and cost discipline reflected in the EBIT and EPS bridges. With the last quarter’s net profit up 101.50% quarter on quarter, the market will focus on whether this momentum is sustainable in the face of a softer year-over-year revenue comparison. Any deviation in gross margin from the 46.52% baseline will be scrutinized, as even small changes can have an outsized impact on the 5.50% net margin profile. Finally, the ability to stabilize EPS around the 8.64 estimate—despite forecast year-over-year declines—will likely determine the stock’s near-term reaction, especially if revenue lands close to the 84.66 billion estimate.
Analyst Opinions
The balance of institutional commentary over the last six months skews cautiously bullish, with a majority pointing to resilient fundamentals despite a softer year-over-year forecast. The supportive camp emphasizes ongoing execution in generics launches and operational efficiency that helped deliver a 101.50% quarter-on-quarter net profit recovery, while acknowledging headwinds from pricing and tougher comparisons. Notably, several analysts highlight that the company’s guidance framework—implying revenue of 84.66 billion, EBIT of 7.20 billion, and EPS of 8.64—sets achievable bars in light of recent cost control and mix optimization, increasing the likelihood of an in-line to modest-beat outcome if gross margins hold near the mid-40s percentage range. The prevailing view is that the stock reaction will be most sensitive to trajectory signals on profitability rather than headline revenue, given the implied 3.46% year-over-year decline already embedded in expectations.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments